These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32022786)

  • 41. The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction.
    Wang X; Verma S; Mason RP; Bhatt DL
    Curr Diab Rep; 2020 Oct; 20(11):65. PubMed ID: 33095318
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?
    Nelson JR; True WS; Le V; Mason RP
    Postgrad Med; 2017 Nov; 129(8):822-827. PubMed ID: 28974128
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical trials of eicosapentaenoic acid (EPA) prescription products for the treatment of hypertriglyceridemia.
    Doggrell SA
    Expert Opin Pharmacother; 2019 Jul; 20(10):1221-1225. PubMed ID: 31038369
    [No Abstract]   [Full Text] [Related]  

  • 44. To treat or not to treat? Questions, controversies in prevention.
    Caffrey MK
    Am J Manag Care; 2014 May; 20(8 Spec No.):E11. PubMed ID: 25617930
    [No Abstract]   [Full Text] [Related]  

  • 45. Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia: Value for Money Analysis.
    Arbel R; Aboalhasan E; Hammerman A; Azuri J
    Am J Med; 2021 Jul; 134(7):e415-e419. PubMed ID: 33450273
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Icosapent Ethyl: Niche Drug or for the Masses?
    Bazarbashi N; Miller M
    Curr Cardiol Rep; 2020 Aug; 22(10):104. PubMed ID: 32770402
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Omega-3 polyunsaturated fatty acids and cardiovascular disease: an emphasis on omega-3-acid ethyl esters 90 for the treatment of hypertriglyceridemia.
    Tatsuno I
    Expert Rev Cardiovasc Ther; 2014 Nov; 12(11):1261-8. PubMed ID: 25319059
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Icosapent Ethyl (Vascepa) for Hyperlipidemia/Hypercholesterolemia to Reduce Risk of Heart Attack and Stroke.
    Myran L; Nguyen TN
    Am Fam Physician; 2021 Jan; 103(2):117-118. PubMed ID: 33448769
    [No Abstract]   [Full Text] [Related]  

  • 49. Epanova(®) and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy.
    Kataoka Y; Uno K; Puri R; Nicholls SJ
    Future Cardiol; 2013 Mar; 9(2):177-86. PubMed ID: 23463969
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Omacor (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia.
    Rupp H
    Adv Ther; 2009 Jul; 26(7):675-90. PubMed ID: 19629408
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A retrospective case series of the lipid effects of switching from omega-3 fatty acid ethyl esters to icosapent ethyl in hyperlipidemic patients.
    Castaldo RS
    Postgrad Med; 2014 May; 126(3):268-73. PubMed ID: 24977343
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Icosapent ethyl for hypertriglyceridaemia and atherosclerosis: greater RESPECT for increased therapeutic use.
    Gaba P; Bhatt DL; Boden WE
    Eur Heart J; 2024 Feb; 45(6):439-442. PubMed ID: 37889071
    [No Abstract]   [Full Text] [Related]  

  • 53. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
    Davidson MH; Stein EA; Bays HE; Maki KC; Doyle RT; Shalwitz RA; Ballantyne CM; Ginsberg HN;
    Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ▼Icosapent ethyl for CV risk reduction.
    Drug Ther Bull; 2024 Sep; 62(9):135-140. PubMed ID: 39242154
    [No Abstract]   [Full Text] [Related]  

  • 55. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options.
    Weintraub H
    Atherosclerosis; 2013 Oct; 230(2):381-9. PubMed ID: 24075771
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Omega-3 polyunsaturated fatty acids (Omacor) for hypertriglyceridemia.
    Med Lett Drugs Ther; 2005 Nov; 47(1221):91. PubMed ID: 16267495
    [No Abstract]   [Full Text] [Related]  

  • 57. Mechanistic Insights from REDUCE-IT STRENGTHen the Case Against Triglyceride Lowering as a Strategy for Cardiovascular Disease Risk Reduction.
    Mason RP; Eckel RH
    Am J Med; 2021 Sep; 134(9):1085-1090. PubMed ID: 33864765
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial.
    Kim CH; Han KA; Yu J; Lee SH; Jeon HK; Kim SH; Kim SY; Han KH; Won K; Kim DB; Lee KJ; Min K; Byun DW; Lim SW; Ahn CW; Kim S; Hong YJ; Sung J; Hur SH; Hong SJ; Lim HS; Park IB; Kim IJ; Lee H; Kim HS
    Clin Ther; 2018 Jan; 40(1):83-94. PubMed ID: 29223557
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología [Spanish Society of Cardiology] and the Sociedad Española de Diabetes [Spanish Diabetes Society].
    Pedro-Botet J; Barrios V; Sánchez-Margalet V; Tamargo J; Arrieta F; Gámez JM; Gimeno-Orna JA; Escobar C; Gómez-Doblas JJ; Pérez A;
    Endocrinol Diabetes Nutr (Engl Ed); 2023 Mar; 70 Suppl 1():51-62. PubMed ID: 36402735
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).
    Bays HE; Braeckman RA; Ballantyne CM; Kastelein JJ; Otvos JD; Stirtan WG; Soni PN
    J Clin Lipidol; 2012; 6(6):565-72. PubMed ID: 23312052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.